一项关于氟伏沙明治疗门诊抑郁症患者的比利时多中心研究。
A Belgian multicentre study of fluvoxamine in depressive outpatients.
作者信息
Brasseur R, Van Moffaert M, Mesotten F, Ansseau M, Uytdenhoef P, Bartholome F
出版信息
Acta Psychiatr Belg. 1985 Sep-Oct;85(5):636-43.
Fluvoxamine, a new antidepressant that specifically inhibits serotonin reuptake, was studied in 272 outpatients in a six-week multicentre trial in Belgium. On the Hamilton Depression Scale, the mean score dropped from 25.2 to 8 after six weeks (p less than 0.00001). The Clinical Global Impression scores showed similar evolution. Fluvoxamine is a real antidepressant with a marked effect on mood. Its effective dosage is 100 mg to 200 mg/day. Its tolerance, notably at the cardiovascular level, is excellent.
氟伏沙明是一种新型抗抑郁药，能特异性抑制5-羟色胺再摄取。在比利时进行的一项为期六周的多中心试验中，对272名门诊患者进行了研究。根据汉密尔顿抑郁量表，六周后平均得分从25.2降至8（p小于0.00001）。临床总体印象评分显示出相似的变化。氟伏沙明是一种真正的抗抑郁药，对情绪有显著影响。其有效剂量为每日100毫克至200毫克。其耐受性极佳，尤其是在心血管方面。
Zotero 插件